RecruitingNot ApplicableNCT05138614

Supporting Treatment Access and Recovery in COD

Supporting Treatment Access and Recovery in Co-Occurring Opioid Use and Mental Health Disorders


Sponsor

University of Massachusetts, Worcester

Enrollment

1,000 participants

Start Date

Mar 11, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This 4-year study will randomize 1,000 people with co-occurring opioid use and mental health disorders (COD) at medication for opioid use disorder (MOUD) clinics to evaluate the effectiveness of MISSION, a multi-component team approach, or its components with MOUD versus MOUD alone, as well as the incremental benefits of MISSION or its components for improving outcomes. We expect that individuals receiving MISSION or its parts + MOUD will show greater improvement over MOUD alone on: engagement, substance use, and mental health.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Are 18 years-old and older;
  • Are fluent in English or Spanish;
  • Have OUD who (a) are newly admitted into the program with OUD; or (b) who have been active in the program for the treatment of OUD with medications like buprenorphine or naltrexone, but experienced a recent relapse with any substance (e.g., alcohol, cocaine, opioids, or benzodiazepines). This second group is necessary to include because patients who may have been stable for a long period of time may have a relapse and need intensive treatment to help them regain their abstinence and facilitate the path towards recovery. Thus, by taking those newly enrolled and those who were stable on MOUD but had a recent relapse, the second group is clinically similar to the first group and the intervention will be meaningful.;
  • Able to provide consent;
  • Potentially have a concurrent substance use disorder in addition to opioids; and

Exclusion Criteria4

  • Are not fluent in English or Spanish;
  • Are acutely psychotic, acutely suicidal with a plan, or homicidal;
  • Are incompetent and unable to provide informed consent; and
  • Have concurrent severe alcohol use disorder or high dose benzodiazepine needing detoxification. This exclusion factor is based on DSM-5 criteria, and those who are currently drinking or with a history of severe alcohol withdrawal (i.e., alcohol related seizures, and delirium tremens) will also be excluded. High dose benzodiazepine is defined as using Lorazepam equivalent of > 10 mg/day; Diazepam > 100 mg/day; Clonazepam 5 mg/ day; Alprazolam 5 mg/day.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMedication for Opioid Use Disorder

medication management

BEHAVIORALMISSION Critical Time Intervention

offering intensive community-based services that decrease in intensity over time

BEHAVIORALMISSION Peer Support

including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders

BEHAVIORALMISSION Dual Recovery Therapy

comprised of 13 structured co-occurring disorders treatment sessions


Locations(5)

Behavioral Health Network

Holyoke, Massachusetts, United States

Behavioral Health Network

Orange, Massachusetts, United States

Behavioral Health Network

Springfield, Massachusetts, United States

UMass Chan Road to Care Clinic

Worcester, Massachusetts, United States

SaVida Health

Worcester, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05138614


Related Trials